

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: 10/1/02

Signature:

(Anna P. Lucey)

RECEIVED

OCT 09 2002

TECH CENTER 1600/2900

Docket No.: CIBT-P10-203
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Scott et al.

Application No.: 09/754032

Group Art Unit: 1646

Filed: January 3, 2001

Examiner: Not Yet Assigned

For: PATCHED GENES AND USES RELATED
THERETO

TECH CENTER 1600/2900

OCT 23 2002

RECEIVED

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
Washington, DC 20231

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned.


A copy of each reference on PTO/SB/08 is attached.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents should one or more of the documents be applied against the claims of the present application.

Dated:

Respectfully submitted,

By 

David P. Halstead, Ph.D.

Registration No.: 44,735

ROPES & GRAY

One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys for Applicant

**EXAMINATION DISCLOSURE CITATION
IN AN APPLICATION**
(Use several sheets if necessary)

OCT 07 2002

Docket Number (Optional)

CIBT-P10-203

Application Number
09/754,032Applicant
Scott et al.

Filing Date

January 3, 2001

Group Art Unit
1646

OCT 23 2002

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

RECEIVED

OCT 09 2002

FOREIGN PATENT DOCUMENTS

TECH CENTER 1600/2900

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation YES NO

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages Etc.)

DT	Hammerschmidt, M. et al. Protein kinase A is a common negative regulator of Hedgehog signaling in the vertebrate embryo. <i>Genes & Development</i> 10, 647-658 (1996).
DU	Noveen, A. et al. cAMP, an Activator of Protein Kinase A, Suppresses the Expression of Sonic Hedgehog. <i>Biochem. Biophys. Res. Comm.</i> 219, 180-185 (1996).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE